However , rates of major and non-major clinically relevant bleeding with rivaroxaban vs. warfarin were higher in patients with SVD ( 19.8 % rivaroxaban vs. 16.8 % warfarin ; HR 1.25 , 95 % CI 1.05-1 .49 ) vs. those without ( 14.2 % rivaroxaban vs. 14.1 % warfarin ; HR 1.01 , 95 % CI 0.94-1 .10 ; interaction P = 0.034 ) , even when controlling for risk factors and potential confounders .